CD274 and esophageal squamous cell carcinoma: In the PFS state, the QALYs produced by nivolumab plus ipilimumab were much lower than that of nivolumab plus chemotherapy for overall advanced ESCC patients, while there was almost identity between the two treatment regiments for PD-L1 positive ESCC patients.